Global Cardiovascular Partnering 2023: Trends, Players and Financials for Every Deal Since 2016

News provided by

Apr 04, 2023, 20:15 ET

DUBLIN, April 4, 2023 /PRNewswire/ -- The "Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Cardiovascular Partnering 2016 to 2023 provides the full collection of cardiovascular disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.

Trends in cardiovascular partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Cardiovascular partnering agreement structure
Cardiovascular partnering contract documents
Top cardiovascular deals by value
Most active cardiovascular dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering cardiovascular deals.

The report presents financial deal terms values for cardiovascular deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of cardiovascular dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cardiovascular dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading cardiovascular deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active cardiovascular dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to cardiovascular deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all cardiovascular partnering deals by specific cardiovascular target announced since 2016. The chapter is organized by specific cardiovascular therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all cardiovascular partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in cardiovascular partnering and dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cardiovascular technologies and products.

Report scope

Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to cardiovascular trends and structure of deals entered into by leading companies worldwide.

Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials includes:

Trends in cardiovascular dealmaking in the biopharma industry since 2016
Access to headline, upfront, milestone and royalty data
Access to over 850 cardiovascular deal records
The leading cardiovascular deals by value since 2016

The report includes deals for the following indications: Abdominal aortic aneurysm, Angina, Arrhythmia, Atrial fibrillation, Long QT syndrome, Supraventricular Tachycardia, Ventricular fibrillation, Ventricular tachycardia, Atherosclerosis, Breathlessness, Cardiogenic shock, Cardiomyopathy (heart muscle disease), Chest pain, Congenital heart disease, Congestive heart failure, Coronary artery disease, Ductus arteriosus, Fatigue, Hypercholesterolemia, Hypertension, Intermittent claudication, Ischemic heart disease, Limb ischemia, Marfan's Syndrome, Myocardial Infarction, Oedema (excess fluid), Palpitations, Peripheral arterial disease, Thrombus (blood clot), Valvular heart disease, Aortic stenosis, Restenosis, Varicose veins, plus other cardiovascular indications.

In Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 850 cardiovascular deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Selection of Companies Mentioned

1A Pharma
3PrimeDx
4D Molecular Therapeutics
4D Pharma
4SC Discovery
36 Strategies General Trading
480 Biomedical
A&D Medical
A&E Medical
A*STAR Agency for Science
Technology and Research
AADi
Abbott Laboratories
Abbott Vascular Devices
Abiomed
Ab Medica
Abyrx
Acasti Pharma
Accenture
Access Scientific
Access Vascular
ACEA Biosciences
Acino Pharma
Actelion
Actuated Cardio Engineering
Actuated Medical
Acutus Medical
ADAS 3D Medical
AddUp
Admedus
Admera Health
Advanced BioScience Laboratories
Advanced Cardiac Therapeutics
Advanced Catheter Therapies
Advanced Cooling Therapy
Adventus Ventures
Aegerion Pharmaceutical
Aerolase
Agena Bioscience
Agilent Technologies
Akcea Therapeutics
Akers Biosciences
Akrimax Pharmaceutical
Akums Drugs and Pharmaceuticals
Alibaba Health
AliveCor
Allegiance Health Foundation
Allergan
Alliance Medical
Alnylam Pharmaceuticals
Altrix Medical
Amarin
Amarna Therapeutics
American College of Emergency Physicians
American College of Physicians Foundation
American College of Surgeons
American Heart/Stroke Association
American Heart Association
AmeriCares
Amgen
Amneal Pharmaceuticals
AmorChem
Amos Gazit
AnaBios
Analog Devices
AnaMar
Angel Medical Systems
AnGes MG
Angiodynamics
Angion Biomedica
Angionetics
AngioSoma
ANI Pharmaceuticals
Antares Pharma
Antaros Medical
Anthem
Anthos Therapeutics
AOP Orphan Pharmaceuticals
APAC Scientific
Apicore
Aplagon
Apollo Hospitals Group
Apotex
Apple
Applied Medical
Aptahem
Aralez Pharmaceuticals
Ardelyx
Arena Pharmaceuticals
argenx
Argon Medical Devices
Armetheon
Aronora
Arrowhead Pharmaceuticals
Arteriae
Arterial Health International
Arterial Remodeling Technologies
Asahi Intecc
Ashland-Boyd County Health Department
ASKA Pharmaceuticals
Aspen Global
Aspen Holding
Aspire Health Science
Astellas Pharma
AstraZeneca
AstraZeneca HealthCare Foundation
Atelerix
Athersys
Atnahs Pharma
AutoGenomics
Autotelic
Aviir Diagnostics
Awamedica
Axiogenesis
Axol Bioscience
Aziyo Biologics
Baker IDI Heart and Diabetes Institute
Bardy Diagnostics
Baxter International
Bayer
Bayer Healthcare
Bay Labs
B Braun
Beijing Leadman Biochemistry
Beijing SL Pharma
Bellerophon Therapeutics
Bened Biomedical
Berg
Bertin Pharma
Bicycle Therapeutics
Bina Technologies
BioCardia
Bioengineering Laboratories
Biofourmis
BioHeart
BioLamina
BIOLIFE4D
BioLife Solutions
Biomerics
BioSig Technologies
Biostar
Biostar Pharmaceuticals
Biotectix
BioTelemetry
Biotricity
Biotronik
BioVectra
Bioventix
Biovic Sdn bhd
Bird Foundation
BlueRock Therapeutics
BodyTrace
Boehringer Ingelheim
Boryung Pharmaceutical
Boston Medical Center
Boston Pharmaceuticals
Boston Scientific
Breckenridge Pharmaceuticals
Brigham and Women's Hospital
Brigham Young University
Bristol-Myers Squibb
Broad Institute
Brooks Automation
Burgerhospital
Cadila Pharmaceuticals
Caladrius Biosciences
California Institute for Regenerative Medicine
California Institute of Technology
Canadian Institutes of Health Research
Capellabio
Capricor Therapeutics
Caprion Proteomics
Cardiac Insight
Cardiac Life
Cardinal Health
CardiNor
Cardio3 Biosciences Asia Holdings
CardioDx
CardioFocus
CardioLogic
Cardiome Pharma
Cardiorentis
Cardiovascular Cell Therapy Research Network
Cardiovascular Research Foundation
Cardiovascular Systems
Cardiowise
Cardium Therapeutics
Cardurion Pharmaceuticals
CareDx
CareLearning
Carestream Health
CareTaker Medical
Carmat
Carmel Pharma
Carrum Health
Casebia Therapeutics
Case Western Reserve University
CASI Pharmaceuticals
CAS Medical Systems
Catherine's Health Center
Catheter Precision
CDC Foundation
Cedars-Sinai Health System
Cedars-Sinai Medical Center
Celgene
Celladon
Cell and Gene Therapy Catapult
CELLINK
CellProThera
Cell Therapy
Celltrion
Cellular Logistics
CeloNova BioSciences
Celyad
Center for Biomarker Research in Medicine
Center for Connected Health
Centers for Medicare and Medicaid Services
Centron Diagnostics
Cevec Pharmaceuticals
Chameleon BioSurfaces
Charles River Laboratories
Chek Diagnostics
Chiesi Farmaceutici
Children's Heart Foundation
Children's Hospital Boston
Children's Hospital of Philadelphia
Children's Medical Research Institute
Children's Hospital Oakland Research Institute (CHORI)
China Grand Pharmaceutical
China Medical System
Chinese Future Industry Investment Fund
Chinese Society of Cardiology
Chong Kun Dang
Christiana Care Health System
Cilag AG
C Illies
CinCor Pharma
Cipher Pharmaceuticals
Cipla Medpro
Citius Pharmaceuticals
Clarity Pharmaceuticals
ClearFlow
Cleveland Clinic
Cleveland HeartLab
Clinlogix
Coeptis Pharmaceuticals
Cofactor Genomics
Colibri Heart Valve
College of Life Science of Northwest University
Columbia University Medical Center
Conavi Medical
Concordia Healthcare
Contatti Medical
Cook Medical
Coqui RadioPharmaceuticals
Cordis
CorDynamics
CoreRx Pharma
Corindus Vascular Robotics
CorMatrix Cardiovascular
Coroneo
CorpMedical
Correvio
CorVascular
Corvia Medical
Corvida Medical
Corvidia Therapeutics
Covalon Technologies
Covance
Covidien
Covis Pharmaceutical
Cranford Pharmaceuticals
CRISPR Therapeutics
Critical Diagnostics
Crown Bioscience
Cryolife
CSL
Cure Duchenne
CVie
CyberHeart
Cyclenium Pharma
Cynata Therapeutics
Cytori Therapeutics
CytoSorbents
Daewoong Pharmaceutical
Daiichi Sankyo
DalCor Pharmaceuticals
Dalhousie University
Dassault Systems
DaVinci Biomedical Research Products
DecImmune Therapeutics
deCODE Genetics
Delta
Deltex Medical
Denovo Biopharma
Department of Defense
Department of Health and Human Services
Dewpoint Therapeutics
Diablo Clinical Research
diaDexus
DiA Imaging Analysis
Diaxonhit
Dicerna Pharmaceuticals
DiNAQOR
Dizal Pharmaceutical
Dogma Therapeutics
Domainex
Dorizoe Lifesciences
Dr. Reddy's Laboratories
Drukier Institute for Children's Health
DSM
Duke-NUS Graduate Medical School Singapore
Duke Clinical Research Institute (DCRI)
Duke University
Duke University Medical Center
Eagle Pharmaceuticals
EB Neuro
eCardio Diagnostics
Eddingpharm
Edwards Lifesciences
Eiger BioPharmaceuticals
Eko
ELC Group
Electrical Geodesics
Elexopharm
Eli Lilly
Elkhorn Logan Valley Public Health Department
Embolitech
EmboMedics
Emory University
Enamine
Endo International
Endologix
Endospan
Endotronix
Enterprise Partners Venture Capital
ENYO Pharma
Epsilon
Erasmus University Medical Center
ERS Genomics
ERT
Esaote
Esperion Therapeutics
Espero Pharmaceuticals
Eurolab Especialidades Medicinales de Eurofar
European Commission
European Innovation Council
Event Cardio Group
Everest Medicines
Excelera Network
Exelixis
Expression Analysis
ExScientia
FABPulous
Feinstein Institute for Medical Research
FEops
FibriCheck
Fine Foods & Pharmaceuticals N.T.M.
First Check Diagnostics
FitBit
Food and Drug Administration (FDA)
Foundation for Community Partnerships
Frankfurt University Hospital
FSD Pharma
Fujifilm
Fujifilm medical systems
Fundacion Progreso y Salud
Fu Wai Hospital
G3 Pharmaceuticals
Galenicum Health
Gardia Medical

For more information about this report visit https://www.researchandmarkets.com/r/f6hila

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets